威尼斯人
医学
髓系白血病
氯法拉滨
肿瘤科
净现值1
阿糖胞苷
血液学
内科学
生物信息学
白血病
癌症研究
生物
生物化学
基因
染色体
核型
慢性淋巴细胞白血病
作者
Kalyan Vara Ganesh Nadiminti,Kieran D. Sahasrabudhe,Hongtao Liu
标识
DOI:10.1186/s13045-024-01632-8
摘要
The AML treatment landscape has significantly changed in recent years with the approval of targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of FLT3 and IDH1/2 mutations. More importantly, approval of the combination of the BCl-2 inhibitor, venetoclax, and hypomethylating agents or low dose cytarabine provided unprecedented breakthrough for the frontline treatment of older, unfit AML patients. Even with all this exciting progress, more targeted therapies for AML treatment are needed. Recent development of menin inhibitors targeting AML with KMT2A rearrangements or NPM1 mutations could represent a promising new horizon of treatment for patients within these subsets of AML. Our current review will focus on a summary and updates of recent developments of menin inhibitors in the treatment of AML, on the challenges ahead arising from drug resistance, as well as on the opportunities of novel combinations with menin inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI